The stock is currently trading above the buyout price, implying that investors expect a sweetened offer
The stock is still cheap by historical standards, but bio valuations are what they are these days I personally still like the vaccine business - you don't have to deal with patent cliffs so I think companies should command higher multiples on earnings than traditional drug cos all things being equal
Market Data 
Markets 
AI
